Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. filings document the regulatory record for a Florida-incorporated regenerative biomaterials company serving wound care, burn and surgical healthcare markets. Form 8-K reports furnish quarterly and annual operating results, earnings materials, Regulation FD investor presentations and material events tied to business updates.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation, pay-versus-performance data and shareholder voting matters. Recent current reports also document restructuring-related officer changes and temporary compensation reductions for named executive officers, linking governance disclosures to changes in the company’s cost structure.
MiMedx Group, Inc. files its annual report describing operations centered on placental allografts, a growing wound-care and surgical portfolio, and recent expansion into xenografts and distribution agreements. The report states $719 million aggregate market value of non-affiliate common equity and 148,566,586 shares outstanding as of February 19, 2026.
The company highlights regulatory engagement with the FDA (including an RFD and litigation concerning AXIOFILL), Medicare reimbursement changes effective January 1, 2026 (a new flat rate of $127.14 per cm2), expansion into Japan with reimbursement at 35,100 Yen/cm2, ongoing clinical evidence generation (including an EPIEFFECT RCT), and strategic priorities to broaden products and grow surgical adoption. Revenue seasonality, reliance on donor tissue, and competitive/reimbursement risks are emphasized.
MiMedx Group, Inc. is holding its 2026 annual shareholder meeting as a virtual-only webcast on June 10, 2026, at 9:00 a.m. Eastern time. Shareholders of record at 5:00 p.m. Eastern time on April 13, 2026, may vote.
Investors are asked to elect seven directors, approve on an advisory basis the Company’s executive compensation, and ratify Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026. The Board unanimously recommends voting in favor of all proposals.
The proxy also discusses 2025 performance, including 20% net sales growth, a 12% GAAP net income margin, a 25% adjusted EBITDA margin, and $74 million of operating cash flow, reflecting strong profitability and cash generation alongside strategic product launches and reimbursement changes.
MiMedx Group, Inc. reported first quarter 2026 net sales of $59 million, down 33% from $88 million a year earlier, as new Medicare reimbursement rules severely pressured its Wound segment. Surgical product sales grew 13% year over year to $36.4 million, while Wound sales fell 60% to $22.6 million.
Gross margin declined to 71% from 81%, mainly due to lower Wound pricing and unfavorable mix. The company posted a net loss of $10.9 million, versus $7.0 million of net income in 2025, and Adjusted EBITDA was a loss of $11.6 million, a margin of negative 19.7%.
MiMedx ended March 31, 2026 with $159.8 million in cash and cash equivalents and net cash of $142 million. For 2026, it now expects net sales of $260–$290 million and approximately breakeven Adjusted EBITDA, and continues to target low double-digit annual net sales growth with Adjusted EBITDA margin above 20% longer term.
MiMedx Group reported Q1 2026 net sales of $59.0 million, down 33.1% from $88.2 million a year earlier, and recorded a net loss of $10.9 million versus prior-year net income of $7.0 million. Wound segment sales fell 59.7% to $22.6 million following January 1, 2026 Medicare reimbursement changes for skin substitutes, while Surgical sales grew 13.2% to $36.4 million.
Gross margin compressed to 70.6% from 81.2%, reflecting lower Wound pricing, an unfavorable mix and higher costs. The company ended the quarter with $159.8 million in cash and equivalents, $44.6 million in current liabilities, and $17.6 million of term debt outstanding, leaving its $75.0 million revolver undrawn.
Operating cash flow was $1.9 million, aided by strong receivables collections. MiMedx invested $5.0 million upfront for exclusive U.S. rights to RegenKit Wound Gel and noted a remaining $1.3 million profit-share obligation to TELA Bio. After quarter-end it announced a cost reduction initiative, including a workforce reduction of about 15% and expected one-time charges of roughly $4 million in Q2 2026.
MiMedx Group, Inc. launched a restructuring and cost reduction initiative to streamline operations and support future profitability. The plan targets approximately $40 million in annualized operating expense savings across the company and will result in a one-time restructuring charge of about $4 million in the second quarter of 2026.
As part of the changes, the position of Chief Operating Officer held by Ricci Whitlow was eliminated; her departure is stated as not due to a disagreement with the company. CEO Joe Capper’s base salary was reduced by 20%, while base salaries for other named executive officers were reduced by 10% through December 31, 2026.
Management notes that the Surgical business is performing well, but the Wound Care business is recovering slowly following a January 1 Medicare reimbursement reduction, prompting the decision to adjust the cost structure.
MIMEDX GROUP, INC. General Counsel and Chief Administrative Officer William Frank Hulse IV reported a tax-related share disposition. On March 13, 2026, 20,245 shares of common stock were withheld at $4.38 per share to cover tax obligations on vesting of restricted stock. After this withholding, he directly holds 543,195 shares of MIMEDX common stock, indicating this was a routine compensation and tax event rather than an open-market trade.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported a routine tax-related share disposition. On March 13, 2026, 6,762 shares of common stock were withheld at $4.38 per share to cover tax obligations on vesting of restricted stock.
These shares were withheld by the company rather than sold in the open market. After this transaction, Maersk-Moller directly owned 329,450 shares of MiMedx common stock.
MIMEDX GROUP Chief Commercial Officer Kimberly Maersk-Moller reported compensation-related share activity. On this Form 4, 42,845 shares of common stock were acquired on March 10, 2026 through the vesting of performance stock units granted on March 13, 2023. Of these, 21,270 shares were withheld to cover tax obligations required by company policy, leaving her with 336,212 shares of common stock owned directly after the transactions.
MIMEDX GROUP General Counsel and CAO William Frank Hulse IV received common shares through the vesting of performance stock units at $4.50 per share. A portion of the vested shares was withheld to cover tax obligations, leaving him with 563,440 directly owned shares after these transactions.
MiMedx Group Chief Financial Officer Doug Rice reported equity compensation activity tied to performance stock units (PSUs). On the reported date, he acquired 243,000 shares of common stock at $4.50 per share upon vesting of PSUs covering the performance period from January 1, 2023 to December 31, 2025.
In connection with this vesting, 96,363 shares were disposed of at $4.50 per share to satisfy tax obligations, with shares withheld as required by company policy rather than sold on the open market. After these transactions, Rice directly held 412,315 shares of MiMedx common stock.